Back to top
more

Acrivon Therapeutics, Inc. (ACRV)

(Real Time Quote from BATS)

$7.22 USD

7.22
6,033

-0.03 (-0.41%)

Updated Jun 17, 2024 10:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca's (AZN) Imfinzi Gets FDA Nod in Expanded Use

by Zacks Equity Research

The FDA approves AstraZeneca's (AZN) Imfinzi in combination with chemotherapy for treating mismatch repair deficient advanced/recurrent endometrial cancer based on data from the phase III DUO-E study.

Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry

by Zacks Equity Research

Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.

Repligen (RGEN) Promotes CCO, Shares Fall on Leadership Change

by Zacks Equity Research

Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.

Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug

by Zacks Equity Research

Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.

Ultragenyx (RARE) Posts New Data From Bone Disease Study

by Zacks Equity Research

Ultragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in patients with osteogenesis imperfecta in new data from the Orbit study.

SAGE's Huntington's Disease Study Meets Primary Endpoint

by Zacks Equity Research

The phase II SURVEYOR study evaluating SAGE's dalzanemdor as a potential treatment for patients with cognition dysfunction caused by Huntington's disease meets its primary endpoint.

Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO

by Zacks Equity Research

Eli Lilly (LLY) CFO Anat Ashkenazi joins Google's parent company Alphabet as CFO and senior vice president, effective from Jul 31, 2024

Here's Why You Should Consider Buying Bioventus (BVS) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Bioventus (BVS) stock now may turn out to be a prudent move.

Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.

Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock

by Zacks Equity Research

Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.

Kinjel Shah headshot

5 Small Drug Stocks to Buy From a Recovering Industry

by Kinjel Shah

Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.

Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Acrivon Therapeutics, Inc. (ACRV) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?

by Zacks Equity Research

Acrivon Therapeutics (ACRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Catalyst's (CPRX) revenues in the first quarter of 2023 are expected to have been driven by Firdapse sales. Updates on generic competition and the commercial launch of Fycompa are expected.